PVI
TGTX icon

Pura Vida Investments’s TG Therapeutics TGTX Stock Holding History

Pura Vida Investments’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-250,000
Closed -$2.96M – 166
2022
Q4 		$2.96M Buy
+250,000
New +$1.81M 0.15% 106

Other funds holding TGTX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JFG
Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Pura Vida Investments's TGTX Position: Q1 2023 in Review

Pura Vida Investments sold out of TG Therapeutics (TGTX) in Q1 2023, closing a stake of 504,829 shares — an estimated $5.97M sold.

Pura Vida Investments first reported a position in TGTX in Q1 2018 and held it in 13 quarters. The position peaked at $7.11M in Q3 2022. 214 funds tracked by Wall St. Rank hold TGTX as of Q1 2023.

  • Pura Vida Investments reported no remaining TG Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Pura Vida Investments sold 504,829 TG Therapeutics shares in Q1 2023, an estimated $5.97M.
  • Pura Vida Investments first reported a position in TG Therapeutics in Q1 2018 and held it in 13 quarters.
  • Pura Vida Investments's TG Therapeutics position peaked at $7.11M in Q3 2022.
  • 214 funds tracked by Wall St. Rank held TG Therapeutics as of Q1 2023.

Based on Pura Vida Investments's 13F filing for Q1 2023, filed 15 May 2023.